search
Gilead Sciences Inc.
Illustrative: Cancer cells. (Pixabay)
From the WebDecember 10, 2017, 2:07 pm
Gilead Sciences acquires CDL for $567m
Globes: Cell Design Labs (CDL) is developing cancer therapies based on CAR T, likely to be the next generation of medications
Kite Pharma develops cell therapies in which the patient's own immune cells fight cancer. (YouTube screenshot)
October 19, 2017, 3:49 pm
Israeli-founded Kite Pharma gets FDA nod for cancer therapy
Firm started by Israeli-US oncologist Arie Belldegrun was acquired by US firm Gilead Sciences for almost $12 billion in August
By Shoshanna Solomon
Weizmann Institute's Prof. Zelig Eshhar holds a board that illustrates how the cancer treatment works with mice. Aug. 29, 2017 (Shoshanna Solomon/Times of Israel)
August 30, 2017, 4:20 pm
Breakthrough Israeli cancer professor on prowl to ease other ills
Weizmann Institute’s Zelig Eshhar’s genetically engineered T-cells are at the heart of Kite Pharma’s $12 billion acquisition
By Shoshanna Solomon
Israeli-American oncologist Arie Belldegrun, founder of Kite Pharma. (YouTube screenshot)
August 28, 2017, 6:55 pm
Gilead to buy Israeli-founded Kite Pharma for nearly $12 billion
The US firm, founded in 2009 by Israeli-US oncologist Arie Belldegrun, develops cell therapies for cancer treatments
By Shoshanna Solomon
Load More